Crescat Capital's latest research letter illustrates the historic countercyclicality of gold mining stocks vs. the broad US ...

Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...

Exact Sciences Corp ( (EXAS) ) has released its Q3 earnings. Here is a breakdown of the information Exact Sciences Corp presented to its ...

Market Leadership and Brand Recognition: Exact Sciences Corp has established itself as a market leader in the cancer screening industry, particularly with its flagship product, Cologuard.

At this time, I would like to welcome everyone to the Exact Sciences. Third quarter ... Next, our rich pipelines of new products including ACO Deette, our blood based CRC screening test and ...

Shares of Exact Sciences Co. (NASDAQ:EXAS – Get Free Report) gapped down prior to trading on Wednesday after the company ...

Exact Sciences Corporation EXAS reported a net loss of 21 cents in third-quarter 2024 compared with break-even earnings in the year-ago quarter. The figure was wider than the Zacks Consensus ...

Market Leadership and Brand Recognition: Exact Sciences Corp has established itself as a market leader in the cancer screening industry, particularly with its flagship product, Cologuard. The ...

Exact Sciences has a multipronged approach to cancer testing. Current products are Cologuard, its flagship stool-based screening test for colorectal cancer, or CRC, and Oncotype DX, its tissue ...

Exact Sciences Exact Sciences shares plunged Wednesday after the company reported widening losses. The maker of the Cologuard colon cancer screening test lowered its full-year outlook.